FDA Accepts Novartis, Kite Pharma’s Personalized Cancer Treatments for Review

The FDA has accepted for review the first two novel, personalized cancer treatments — known as chimeric antigen receptor T-cell therapies, or CAR-T — using immune system cells drawn from the blood and reprogrammed to target cancer cells.
Source: Drug Industry Daily